文献速递慢性肾脏病肾血管病与高血压

慢性肾脏病妊娠期膳食硝酸盐补充的随机试验(ORCHARD-BEET)

Randomized Trial of Dietary Nitrate Supplementation in CKD Pregnancy (ORCHARD-BEET).
PubMed 文献 · Kidney Int Rep · 2026-07-17

ORCHARD-BEET 是一项在英国 8 个中心开展的随机对照可行性试验,纳入 108 例 G2–G5 期慢性肾脏病(CKD)且孕周 <25 周的孕妇,随机接受标准治疗或每日甜菜根汁(膳食硝酸盐 400 mg)。主要结局为招募率,结果为 1.01 例/中心/月(SD 0.90)。在孕前 eGFR <45 ml/min/1.73 m² 的孕妇中,膳食硝酸盐组产后肌酐中位数趋于更低,但差异无统计学意义;膳食硝酸盐组严重不良事件(SAE)更少(P=0.02),提示可能对母体肾脏及新生儿有益,仍需更大样本的随机对照试验验证疗效。

要点

  • 膳食硝酸盐 400 mg/日用于 CKD 孕妇的可行性试验达到招募目标(1.01 例/中心/月)。
  • 孕前 eGFR <45 者产后肌酐有降低趋势,但差异无统计学意义。
  • 膳食硝酸盐组 SAE 更少(P=0.02),但需警惕这是可行性试验的次要/安全性结果。

核心结论

  • 在多中心可行性随机试验中,CKD 孕妇对每日膳食硝酸盐 400 mg 的干预招募可行,并提示母体肾脏和新生儿可能获益,但疗效需更大样本的随机对照试验证实。

研究设计与样本

  • 研究为在英国 8 个中心开展的随机对照可行性试验,纳入孕周 <25 周的 G2–G5 期 CKD 孕妇,随机分为标准治疗组或每日甜菜根汁(膳食硝酸盐 400 mg)组,共 108 例(每组 54 例)。

主要发现

  • 总体招募率为 1.01 例/中心/月(SD 0.90)。
  • 孕前 eGFR <45 ml/min/1.73 m² 的孕妇中,膳食硝酸盐组产后 6 周肌酐中位数 176 μmol/l(IQR 165–194) vs 标准治疗组 226 μmol/l(IQR 169–296),P=0.23;产后 6 个月 173 μmol/l(IQR 152–175) vs 216 μmol/l(IQR 149–295),P=0.18。
  • 新生儿病房或 NICU 入住率在膳食硝酸盐组为 7/30(23.3%),标准治疗组为 21/53(39.6%),P=0.13。
  • 膳食硝酸盐组 7 例(23.3%)发生 11 次 SAE,标准治疗组 27 例(50.9%)发生 53 次 SAE,P=0.02。
  • 事后分析显示,膳食硝酸盐组孕期使用降压药的比例更低(11/30 [36.7%] vs 35/53 [66.0%],P=0.01)。

临床怎么用

  • 目前证据尚不足以将膳食硝酸盐补充作为 CKD 孕妇的常规治疗,需在更大规模随机对照试验证实疗效前谨慎使用。

局限性

  • 研究为可行性试验,样本量小,临床结局的组间比较多为探索性且未达统计学显著性。
  • 部分分析(如降压药使用)为事后分析,证据级别有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Nearly half of pregnant women with moderate-to-severe chronic kidney disease (CKD) will require dialysis or lose ≥ 25% kidney function by 12 months after delivery with high rates of neonatal complications. No targeted approaches have been developed to improve maternal outcomes. METHODS: Pregnant women with stage G2 to G5 CKD (< 25 weeks' gestation) at 8 centers in the UK were randomized to standard care or daily beetroot juice (dietary nitrate 400 mg) within an observational cohort. Exclusions were established dialysis, age < 18 years, major congenital fetal abnormality, multifetal pregnancy, and beetroot allergy. The primary outcome was recruitment rate/site/mo. Secondary outcomes included feasibility measures as well as maternal and fetal or neonatal clinical and safety events. RESULTS: 108 participants were randomized (54/arm); overall mean recruitment rate was 1.01/site/mo (SD: 0.90). Women receiving dietary nitrate with prepregnancy estimated glomerular filtration rate (eGFR) < 45 ml/min per 1.73 m2 tended to have lower median creatinine (Cr) concentrations postpartum than those on standard care (6 weeks: Cr, 176 [interquartile range, IQR: 165-194] μmol/l vs. 226 [IQR: 169-296] μmol/l, P = 0.23; 6 months: Cr, 173 [IQR: 152-175] μmol/l vs. 216 [IQR: 149-295] μmol/l, P = 0.18). Admission to a neonatal unit or neonatal intensive care unit (NICU) tended to be lower with dietary nitrate than with standard care (7/30 [23.3%] vs. 21/53 [39.6%], P = 0.13). Seven women receiving dietary nitrate (23.3%) experienced 11 serious adverse events (AEs, SAEs) compared with 27 women receiving standard care (50.9%) who had 53 SAEs (P = 0.02). In post hoc analysis, fewer participants in the dietary nitrate group took antihypertensive medications during pregnancy (11/30 [36.7%] vs. 35/53 [66.0%], P = 0.01). CONCLUSION: We successfully recruited to a multicenter interventional study of pregnant people with CKD with suggestion of maternal kidney and neonatal benefit. Further evidence of efficacy is needed from a powered randomized controlled trial.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Smith P, Ashworth D, Hung R, et al. Randomized Trial of Dietary Nitrate Supplementation in CKD Pregnancy (ORCHARD-BEET). Kidney Int Rep. 2026. PMID: 42662908. doi:10.1016/j.ekir.2026.106704

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。